“…one of the physicians managing a trial of Xyotax was asked to participate in a conference call for investors, most of whom managed hedge funds. The call was supposed to be about two other cancer drugs, but the analyst threw in a question about Xyotax. The physician answered by expressing concern that some of the clinical trials were being done in Eastern Europe. ‘Boom! Our stock went down,’ Bianco recalls.”
Market Data 
Markets 
AI
